Intellia Therapeutics WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Branche: Chemie/Pharma

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress https://www.globenewswire.com/news-release/2022/05/05/2436692/0/en/Intellia-Therapeutics-Announces-First-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference https://www.globenewswire.com/news-release/2022/05/02/2433370/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-CRISPR-Engineered-Allogeneic-Platform-at-the-2022-Keystone-Symposia-s-Precision-Genome-Engineering.html • Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapy • Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of CD30-expressing hematologic cancers

Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch https://www.fiercebiotech.com/biotech/intellias-1st-ex-vivo-cell-therapy-aml-secures-fda-orphan-drug-status-week-after-trial

Na scheint gerade eher nach hinten los zu gehen 😂

Sehr schön! Intellia hat eben ein Press Releases veröffentlicht mit einer Stellungnahme. Liest sich für mich soweit neutral bis positiv. Ich hoffe, dass dies nun die Investoren wieder zurück holt und sich der Kurs somit auch wieder erholt.

Intellia Therapeutics Sinks as Patent Ruling Overshadows Crispr Promise https://www.bloomberg.com/news/articles/2022-03-01/intellia-sinks-after-patent-ruling-overshadows-crispr-promise • Uncertainty from decision compounds gene-editing stock malaise • Questions could add fuel to a broader biotech retrenchment Intellia Therapeutics Inc. fell by the most in more than five years after the gene-editing company suffered a significant legal setback on the same day it unfurled promising early data on its leading drug candidate. The Cambridge, Massachusetts-based biotechnology company is one of a throng of firms racing to bring new therapies based on the gene-editing technology Crispr to market. On Monday, the U.S. Patent and Trademark Office invalidated a key patent Intellia licensed, casting a cloud of uncertainty over how much the company will be able to profit from the drugs it is developing.  ... The company said in a statement that it is reviewing the patent decision, which it said doesn’t affect any of its ongoing research and development plans. Intellia has leapfrogged competitors by editing faulty genes inside the human body. On Monday, Intellia showed its experimental Crispr therapy significantly decreased harmful protein in patients with a deadly liver disease.  Nevertheless, investors have become wary of gene-editing stocks in the past year. Intellia shares have shed more than half their market value since hitting a 52-week high in September. Crispr Therapeutics AG has shed nearly two-thirds of its value since a recent peak in June. The company said Monday its programs will continue to advance and aren’t affected by the ruling. ...

Mhhh wenn ich jetzt alles richtig verstanden habe, muss Intellia jetzt aber einen Lizenzvertrag mit dem Patentinhaber abschließen oder? Ansonsten können sie ja nicht weiter machen. Oder ?

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein https://www.globenewswire.com/news-release/2022/02/28/2393640/0/en/Intellia-and-Regeneron-Announce-Updated-Phase-1-Data-Demonstrating-a-Single-Dose-of-NTLA-2001-an-Investigational-CRISPR-Therapy-for-Transthyretin-ATTR-Amyloidosis-Resulted-in-Rapid.html • Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels • Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months • NTLA-2001 was generally well tolerated at all dose levels • On track to initiate polyneuropathy dose-expansion cohort (Part 2) in Q1 2022

https://www.globenewswire.com/news-release/2022/02/24/2391296/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Highlights-Recent-Company-Progress.html Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies https://www.globenewswire.com/news-release/2022/02/23/2390327/0/en/Intellia-Therapeutics-Enters-Lease-Agreement-to-Build-Manufacturing-Facility-for-its-CRISPR-based-Therapies.html • State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies • New facility in Waltham, Massachusetts expected to be operational in 2024